Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors

Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors

Abstract Background Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can also influence susceptibility. Methods Patients with disease progression o...

Full description

Bibliographic Details
Main Authors: Miguel A. Villalona-Calero, John P. Diaz, Wenrui Duan, Zuanel Diaz, Eric D. Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Guardiola, Sara Garrido, Muni Rubens, Fernando DeZarraga, Hao Vuong
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Biomarker Research
Subjects:
FancD2
Homologous recombination
Immune checkpoint inhibitor
Biomarkers
DNA repair
Fanconi
Online Access:https://doi.org/10.1186/s40364-022-00386-0

Internet

https://doi.org/10.1186/s40364-022-00386-0

Similar Items